New Delhi: Hyderabad-based drugmaker Hetero has announced the launch of its generic semaglutide portfolio in emerging international markets.
In a phased global push, the company plans to roll out its portfolio product across over 75 countries and initial launches are underway in Africa, Asia, and the Middle East.
Hetero will market three brands Truglyx, Rolmod| and Moto G in multi-dose disposable pen devices targeting both primary indications — type-2 diabetes and weight-loss.
The once-weekly therapy will be available in five dosage strengths — 0.25 mg, 0.5 mg, 1 mg, 2 mg, 1.7 mg and 2.4 mg.
In India, the company is advancing through late-stage clinical trials (Phase-3) and plans to launch the drug after securing regulatory approval.
The company has not disclosed the market price of its brands.
“We have developed a single, global-quality product platform and our goal is to offer a high-quality, affordable generic semaglutide to patients across emerging markets,” said Dr Vamsi Krishna Bandi, MD, Hetero.
“Leveraging our established commercial networks across Asia, the Middle East, Africa, and Latin America, we remain focused on expanding access to high-quality therapies in the diabetes and metabolic care space, while ensuring a consistent global supply,” he added.
Semaglutide, a blockbuster GLP-1 receptor against has lost or is nearing the loss of its patent exclusivity across multiple markets, such as Canada, China, Brazil etc, and generic drugmakers across the globe are gearing to ride the surge of the world’s fastest-growing therapeutic space.
The molecule’s patent cliff marks a watershed moment in the anti-obesity therapeutic landscape, and is expected to redefine the market’s growth trajectory—shifting from value-driven expansion to stronger volume gains while improving access through a range of alternative options.
In India, the molecule’s patent expired on March 21 and more than a dozen brands entered the market on the first day itself. Sources indicate that over 50 brands in total are expected to become available in the near future.
